GlassScriptPhysician profile
Donna C Ware
NPI 1649676222
$1,220.72
in general payments reported to CMS, 2019-2025
12 companies · $16.53 in 2025
The $16.53 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $256 · 2024: $948 · 2025: $16.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,182 · Education: $38.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,182.22 |
| Education | $38.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $548.77 | 2023-2025 | |
| Amgen INC. | $180.36 | 2024 | Enbrel, Otezla, Tavneos |
| Astrazeneca Pharmaceuticals LP | $122.30 | 2023-2024 | Saphnelo |
| Sobi, INC | $93.33 | 2023-2024 | |
| Janssen Biotech, INC. | $79.29 | 2024 | Tremfya |
| Scilex Pharmaceuticals INC. | $50.81 | 2024 | |
| Ucb, INC. | $44.81 | 2024 | Cimzia |
| Genentech USA, INC. | $23.95 | 2024 | Actemra |
| Lilly USA, LLC | $22.73 | 2024 | Taltz |
| Mallinckrodt Hospital Products INC. | $21.64 | 2024 | Acthar |
| Fresenius Kabi USA, LLC | $19.89 | 2024 | Idacio |
| Sandoz INC. | $12.84 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.